Whitening application of stigmastane mixture

By using stigmasterane mixture to inhibit tyrosinase activity, the safety hazards and insufficient stability of existing whitening ingredients were solved, and a pure natural and safe whitening effect was achieved, providing effective whitening for skin topical agents and health foods. Brighten skin care ingredients.

CN118902897APending Publication Date: 2024-11-08SHANGHAI JAHWA UNITED +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410969434.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing whitening ingredients such as hydroquinone, arbutin, kojic acid, etc. have safety hazards, poor stability or slow performance, making it difficult to find pure natural, safe and without side effects, especially in inhibiting tyrosinase activity. There is a lack of effective plant extracting ingredients.

Method used

By significantly inhibiting the activity of tyrosinase, using the mixture of stigmasterane (a mixture of stigmasterane-22-ene-3,6-dione and 5α-stigmasterane-3,6-dione) as a functional additive, Reduce the melanin content in melanocytes and is used to prepare skin topical agents, medicines and health foods with whitening effects.

Benefits of technology

Sculptanane mixture can significantly inhibit tyrosinase activity, significantly reduce melanin content, achieve whitening effect, and show safe, stable and effective whitening and brightening skin care effects in the use of skin topical agents and health foods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004952976910000021
    Figure BDA0004952976910000021
  • Figure BDA0004952976910000022
    Figure BDA0004952976910000022
  • Figure BDA0004952976910000111
    Figure BDA0004952976910000111
Patent Text Reader

Abstract

The invention provides a whitening application of a stigmastane mixture. The invention also relates to an application of the stigmastane mixture in preparation of skin external preparations, medicines and health-care foods with a whitening effect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of natural drug chemistry, and in particular to the whitening application of a stigmasterane mixture and the application of the stigmasterane mixture in the preparation of a skin external preparation, a medicine and a health food with whitening effect. Background Art

[0002] Limited by their own skin color and influenced by aesthetic concepts such as "white is beautiful", whitening has always been the main effect pursued by Asian consumers. The most important factor that determines skin color is the melanin content. The molecular mechanism of most whitening ingredients is to improve skin color by reducing the production of melanin.

[0003] The biosynthesis of melanin involves a series of enzymatic reactions, among which tyrosinase is the key rate-limiting enzyme in the biosynthesis pathway of melanin. Tyrosinase is widely distributed in microorganisms, animals, plants and the human body. It is a copper-containing metalloenzyme that catalyzes the oxidation of tyrosine into dopa, dopaquinone, dopachrome, dihydroxyindole / dihydroxyindolecarboxylic acid, and finally forms melanin. Tyrosinase is one of the key catalytic enzymes in the synthesis of melanin. It plays an important catalytic role in the formation of melanin and its arrival in the epidermis. Tyrosinase activity is closely related to the level of melanin synthesis. In view of this, most of the whitening ingredients on the market start by inhibiting tyrosinase activity, reducing melanin content, and achieving the effect of skin whitening.

[0004] At present, the representative ingredients on the market that achieve whitening effects by inhibiting tyrosinase activity include hydroquinone, arbutin, kojic acid, azelaic acid, etc., but these ingredients often have disadvantages such as safety risks, poor stability or slow efficacy. Finding pure natural, safe and side-effect-free whitening active ingredients has become one of the research hotspots at home and abroad in recent years. Among them, plant extracts, especially Chinese herbal active ingredients, have received more and more attention due to their natural origin, mildness and safety.

[0005] The stigmasterane mixture can be separated and purified from plants such as chamomile and Ailanthus altissima. The stigmasterane mixture is a mixture of stigmasterane-22-ene-3,6-dione and 5α-stigmasterane-3,6-dione in a ratio of about 1:1 (by weight).

[0006] English name: Stigmasta-22-ene-3,6-dione, CAS number: 88661-99-8, molecular weight: 426.7, molecular formula: C 29 H 46 O 2 The structural formula of stigmasterane-22-ene-3,6-dione is:

[0007]

[0008] 5α-stigmastan-3,6-dione English name: 5α-stigmasta-3,6-dione, CAS number: 22149-69-5, molecular weight: 428.7, molecular formula: C 29 H 48 O 2 The structural formula of 5α-stigmasterane-3,6-dione is:

[0009]

[0010] The molecular weight of the stigmasterane mixture is the average molecular weight of the two: 427.7.

[0011] Wang Yuan analyzed the compound components in Croton tiglium and isolated 29 compounds from the 95% ethanol extract of its stem, including stigmasterane-22-ene-3,6-dione; Feng Yalong isolated and identified 33 compounds from the ethyl acetate part of the 80% methanol extract of Plantago, including 5α-stigmasterane-3,6-dione; Chang Xuejian isolated and identified 24 monomer compounds from the active fraction of Scutellaria baicalensis, including 5α-stigmasterane-3,6-dione. Tu Pengfei extracted and purified litchi kernels using 70% ethanol and finally identified 13 compounds, including stigmasterane-22-ene-3,6-dione and 5α-stigmasterane-3,6-dione. Although there are many papers reporting on the separation and purification of stigmasterane mixtures, none of them have studied the biological activity of stigmasterane mixtures, especially the skin care effects.

[0012] The present invention unexpectedly discovered that the stigmasterane mixture can significantly inhibit the activity of tyrosinase, reduce the melanin content in melanocytes, and has a whitening effect. Summary of the invention

[0013] In one aspect, the present invention relates to the use of a stigmasterane mixture for skin whitening.

[0014] In a preferred embodiment, the stigmasterane mixture is used at a concentration of at least 0.02 mg / L, preferably at least 0.2 mg / L. In a preferred embodiment, the stigmasterane mixture is used at a concentration of 0.2 mg / L to 50000 mg / L.

[0015] In a preferred embodiment, the whitening is to inhibit tyrosinase activity, inhibit melanin production, inhibit spot production or a combination thereof.

[0016] On the other hand, the present invention provides the use of the stigmasterane mixture in the preparation of external skin preparations, medicines and health foods with whitening effects.

[0017] In a preferred embodiment, the content of the stigmasterane mixture in the external skin preparation, medicine and health food is 0.00001-10% by weight, preferably 0.0001-5% by weight.

[0018] In a preferred embodiment, the skin external preparation is selected from: facial cream, lotion, gel, toner, essence, facial mask, eye cream, aerosol cleansing foam, spray, shower gel, or facial cleanser. DETAILED DESCRIPTION

[0019] The invention relates to the whitening effect of a stigmasterane mixture, and for the first time finds that the stigmasterane mixture can be used as an effective additive to prepare skin external preparations, medicines and health foods to achieve whitening and brightening skin care effects.

[0020] In order to provide a more concise description, some quantitative expressions given herein are not modified by the term "about". It should be understood that, whether or not the term "about" is explicitly used, each quantity given herein is intended to refer to the actual given value, and is also intended to refer to the approximate values ​​of these given values ​​that can be reasonably inferred by ordinary technicians in the field, including the approximate values ​​of these given values ​​caused by experimental and / or measurement conditions.

[0021] To provide a more concise description, some quantitative expressions herein are described as a range of about X amount to about Y amount. It should be understood that when describing a range, the range is not limited to the upper and lower limits described, but should include the entire range of about X amount to about Y amount or any amount therebetween.

[0022] The stigmasterane mixtures described herein may optionally be in finished packaging form. In one embodiment, the packaging is a container such as a plastic, metal or glass tube or jar containing the stigmasterane mixture. The product may additionally have packaging such as a plastic or cardboard box for storing the container. In one embodiment, the product comprises the stigmasterane mixture and has instructions for guiding the user to apply the stigmasterane mixture to the skin to treat the skin. Such instructions may be printed on the container, a label insert, or any other packaging.

[0023] As used herein, "topical application" means applying or spreading directly onto the external skin, scalp, or hair, for example, using the hands or an application device such as a wipe, roller, or spray.

[0024] As used herein, "cosmetically acceptable" means that the ingredients described by the term are suitable for use in contact with tissue (eg, skin or hair) without undue toxicity, incompatibility, instability, irritation, allergic response, or the like.

[0025] Stigmasterane mixture

[0026] The present invention relates to the whitening effect of a compound stigmasterane mixture. In research, it is found that the stigmasterane mixture can significantly inhibit the activity of tyrosinase, reduce the melanin content in melanocytes, and has a whitening effect. Therefore, the stigmasterane mixture can be used as an effective additive for preparing skin external preparations, medicines and health foods to achieve a whitening and brightening skin care effect.

[0027] In skin whitening applications, the stigmasterane mixture is used at a concentration of at least 0.2 mg / L, preferably at least 0.5 mg / L.

[0028] In a preferred embodiment, the stigmasterane mixture is used at a concentration of 0.2 mg / L to 50000 mg / L, preferably 0.2 mg / L to 5000 mg / L, 0.2 mg / L to 500 mg / L, or 0.2 mg / L to 100 mg / L.

[0029] In some embodiments, the stigmasterane mixture is used at a concentration of 106.95-427.7 mg / L.

[0030] Skin external preparations, medicines and health foods containing stigmasterane mixtures

[0031] The stigmasterane mixture of the present invention can be used as an effective additive in skin external preparations, medicines and health foods.

[0032] The content of the stigmasterane mixture in external skin preparations, medicines and health foods is 0.00002-10% by weight, more preferably 0.0001-5% by weight.

[0033] In some embodiments, the drug is selected from the group consisting of tablets, capsules, emulsions, suspensions, powders, granules, solutions, and various pharmaceutical dosage forms known in the art. Different dosages are added according to different types of dosage forms.

[0034] Health food is also called functional food. It has the function of regulating human body functions, but is not for the purpose of treating diseases, and is suitable for consumption by specific groups of people. In some embodiments, the health food can be in powder form.

[0035] In some embodiments, the preparation is selected from the group consisting of: cream, lotion, gel, toner, essence, mask, eye cream, aerosol (cleansing foam), spray, shower gel and facial cleanser. Different amounts are added according to different types of preparations.

[0036] The skin external preparation is a general concept for all ingredients usually used on the outside of the skin, for example, it can be a cosmetic composition. The cosmetic composition can be a basic cosmetic, a facial makeup cosmetic, a body cosmetic, a hair care cosmetic, etc., and there is no special restriction on its dosage form, which can be reasonably selected according to different purposes. The cosmetic composition also contains different media or matrix excipients allowed by the cosmetics level according to different dosage forms and purposes.

[0037] The skin topical preparation comprising the stigmasterane mixture can be topically applied to human skin and / or hair. The skin topical preparation can also include a cosmetically acceptable topical carrier, which can be about 50% by weight to about 99.99% by weight of the skin topical preparation (such as about 80% by weight to about 99% by weight of the skin topical preparation). In a preferred embodiment of the present invention, the cosmetically acceptable topical carrier comprises water. The cosmetically acceptable topical carrier may include one or more selected from wetting agents, emollients, grease, wetting agents and similar substances. In one embodiment, the cosmetically acceptable topical carrier comprises a substrate such as a nonwoven fabric or a membrane material.

[0038] Skin external preparations, medicines and health foods can be prepared into various product types, including but not limited to lotions, creams, gels, sticks, sprays, ointments, clean liquid lotions and solid soaps, shampoos and hair conditioners, hair fixatives, pastes, foams, powders, mousse, shaving creams, wipes, patches, hydrogels, film-forming products, facial masks and skin films, films and cosmetics such as foundation and mascara. These product types can contain several types of cosmetically acceptable topical carriers, including but not limited to solutions, suspensions, emulsions (e.g., microemulsions and nanoemulsions), gels, solids and liposomes.

[0039] Skin topical preparations, medicines and health foods containing the stigmasterane mixture can be formulated into solutions. The solution usually contains an aqueous solvent or an organic solvent (e.g., about 50% to about 99.99% or about 90% to about 99% of a cosmetically acceptable aqueous solvent or organic solvent). Examples of suitable organic solvents include propylene glycol, polyethylene glycol, polypropylene glycol, glycerol, 1,2,4-butanetriol, sorbitol esters, 1,2,6-hexanetriol, ethanol and mixtures thereof.

[0040] Skin topical preparations can be formulated into solutions containing emollients. Such skin topical preparations preferably contain from about 2% to about 50% of one or more emollients. As used herein, "emollient" refers to a substance used to prevent or alleviate dryness, for example, by preventing the loss of skin moisture through the skin. Examples of emollients include, but are not limited to, vegetable oils, mineral oils, aliphatic esters, etc.

[0041] Lotions can be prepared from such solutions.Lotions typically contain from about 1% to about 20% (e.g., from about 5% to about 10%) of one or more emollients and from about 50% to about 90% (e.g., from about 60% to about 80%) water.

[0042] Another type of product that can be formulated from a solution is a cream. Creams typically contain from about 5% to about 50% (e.g., from about 10% to about 20%) of one or more emollients and from about 45% to about 85% (e.g., from about 50% to about 75%) water.

[0043] Although it is preferred that the skin external preparations, medicines and health foods containing the stigmasterane mixture contain water, as an alternative, the skin external preparations, medicines and health foods may be anhydrous or an ointment containing no water but organic and / or silicone solvents, greases, lipids and waxes. The ointment may contain a simple base of animal or vegetable oils or semisolid hydrocarbons. The ointment may contain about 2% to about 10% of one or more emollients and about 0.1% to about 2% of one or more thickeners.

[0044] The topical agent for skin application can be formulated as an emulsion. If the topical carrier is an emulsion, about 1% to about 10% (e.g., about 2% to about 5%) of the topical carrier contains one or more emulsifiers. The emulsifier can be nonionic, anionic or cationic. Examples of suitable emulsifiers include those commonly identified as suitable emulsifiers in the field of personal care and cosmetic formulations.

[0045] Lotions and creams can be formulated as emulsions. Typically such lotions contain 0.5% to about 5% of one or more emulsifiers. Such creams typically contain about 1% to about 20% (e.g., about 5% to about 10%) of one or more emollients; about 20% to about 80% (e.g., 30% to about 70%) of water; and about 1% to about 10% (e.g., about 2% to about 5%) of one or more emulsifiers.

[0046] Oil-in-water and water-in-oil type single emulsion skin care preparations, such as lotions and creams, are well known in the cosmetics field and can be used in the present invention. Multiphase emulsion skin external preparations (such as water-in-oil-in-water type and oil-in-water-in-oil type) can also be used in the present invention. Generally, such single-phase emulsions or multiphase emulsions contain water, emollients and emulsifiers as their basic ingredients.

[0047] Skin topical preparations, medicines and health foods containing the stigmasterane mixture can also be formulated into gels (e.g., aqueous gels, alcoholic gels, alcohol / water gels or oily gels using suitable gelling agents). Suitable gelling agents for aqueous gels and / or alcoholic gels include, but are not limited to, natural gums, acrylic acid and acrylate polymers and copolymers, and cellulose derivatives (e.g., hydroxymethyl cellulose and hydroxypropyl cellulose). Suitable gelling agents for oils (e.g., mineral oils) include, but are not limited to, hydrogenated butylene / ethylene / styrene copolymers and hydrogenated ethylene / propylene / styrene copolymers. Such gels typically contain between about 0.1% and 5% by weight of such gelling agents.

[0048] The topical skin preparation comprising the stigmasterane mixture may also be formulated as a solid preparation (eg, a wax-based stick, a bar soap, a powder, or a wipe containing a powder).

[0049] In addition to the above-mentioned components, the external preparation for skin which can be used in the present invention may contain various other oil-soluble substances and / or water-soluble substances at levels conventionally established in its technical field for use in external preparations for skin for use on skin and hair.

[0050] The skin external preparation of the present invention may contain additional components commonly found in skin care compositions, such as emollients, skin regulators, emulsifiers, preservatives, antioxidants, fragrances, chelating agents, etc., as long as they are physically and chemically compatible with other components in the skin external preparation and do not affect the effects of the stigmasterane mixture of the present invention.

[0051] In some embodiments of the skin topical preparation of the present invention, one or more preservatives may be used. Suitable preservatives include p-hydroxyacetophenone, C1-C4 alkyl parahydroxybenzoate and phenoxyethanol. Based on the total weight of the composition, the amount of the preservative is about 0.5 to about 2 weight %, preferably about 0.5 to 1 weight %.

[0052] In one example of the skin external preparation of the present invention, one or more antioxidants can be used. Suitable antioxidants include butylated hydroxytoluene (BHT), ascorbyl palmitate (BHA), butylated hydroxyanisole, phenyl-α-naphthylamine, hydroquinone, propyl gallate, nordihydroguaiaretic acid, vitamin E or vitamin E derivatives, vitamin C and its derivatives, calcium pantothenate, green tea extract and mixed polyphenols, and mixtures of the above-mentioned substances. The antioxidant used is about 0.02 to 0.5 weight % of the total weight of the composition, and more preferably from about 0.002 to 0.1 weight % of the amount used.

[0053] In one example of the skin external preparation of the present invention, one or more emollients can be used to act as lubricants through their ability to remain on the skin surface or in the stratum corneum to reduce flaking and improve the appearance of the skin. Typical emollients include fatty esters, fatty alcohols, mineral oils, polyether silicone copolymers, and the like. Examples of suitable emollients include, but are not limited to, polypropylene glycol ("PPG")-15 stearyl ether, PPG-10 cetyl ether, Steareth-10, Oleth-8, PPG-4 lauryl ether, vitamin E acetate, lanolin, cetyl alcohol, cetearyl ethylhexanoate, cetearyl alcohol, glyceryl stearate, hydroxystearate octyl, dimethyl polysiloxane, and combinations thereof. Cetyl alcohol, cetearyl ethylhexanoate, cetearyl alcohol, glyceryl stearate, and combinations thereof are preferred. When used, the emollient is used in an amount ranging from about 0.1 to about 30% by weight, preferably about 1 to about 30% by weight, based on the total weight of the composition.

[0054] In one example of the skin external preparation of the present invention, one or more moisturizers can be used. Moisturizers are also called humectants, which help to improve the effect of emollients, reduce flaking, remove the scales of the composition and improve the touch of the skin. Polyols can be used as moisturizers, including but not limited to glycerol, polyalkylene glycols, alkylene polyols and derivatives thereof, including butylene glycol, propylene glycol, dipropylene glycol, polyglycerol, polyethylene glycol and derivatives thereof, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1,3-dibutylene glycol, 1,2,6-hexanetriol, ethoxylated glycerol, propoxylated glycerol, and combinations thereof. When used, the amount of moisturizer is about 0.1 to about 20% by weight, preferably about 1 to about 15% by weight, based on the total weight of the composition.

[0055] In an example of the skin external preparation of the present invention, one or more emulsifiers can be used. Emulsifiers can be used within the scope of effective stabilizing amount. Preferably, based on the total weight of the composition, the emulsifier is used in an amount of about 1.0 to about 10.0 weight %, more preferably about 3.0 to about 6.0 weight %. Any emulsifier compatible with the components in the composition can be used. Suitable emulsifiers include stearic acid, cetyl alcohol, glyceryl stearate, lecithin, stearyl alcohol, Steareth-2, Steareth-20, acrylic acid (ester) class / C10-30 alkyl alcohol acrylate cross-linked polymer, and combinations thereof.

[0056] In one example of the skin external preparation of the present invention, one or more pH regulators can be used. The pH regulator useful in the skin external preparation of the present invention includes tromethamine. When used, the amount of the pH regulator based on the total weight of the composition is about 0.1 to about 2 weight %, preferably about 0.1 to about 1 weight %.

[0057] In a specific embodiment of the present invention, the skin topical agent comprises acrylates / C10-30 alkyl acrylate crosspolymer, glycerin, p-hydroxyacetophenone, glyceryl stearate and lecithin, cetearyl alcohol, cetearyl ethylhexanoate, tromethamine or a combination thereof.

[0058] Additional cosmetic active agents

[0059] In some embodiments, the topical skin preparation may also include additional cosmetic active agents. As used herein, "cosmetic active agents" are compounds (such as synthetic compounds or compounds isolated from natural sources or natural extracts) that have cosmetic or therapeutic effects on skin or hair, including but not limited to anti-acne agents, oil control agents, antimicrobial agents, anti-inflammatory agents, antifungal agents, antiparasitic agents, topical analgesics, sunscreens, photoprotectants, antioxidants, keratolytic agents, surfactants, moisturizers, nutrients, vitamins, energy enhancers, antiperspirants, astringents, deodorants, curing agents, anti-hard cuticle agents, and agents for hair and / or skin conditioning.

[0060] In one embodiment, these cosmetic actives are selected from (but not limited to): hydroxy acids, benzoyl peroxide, D-panthenol, octyl methoxycinnamate, titanium dioxide, octyl salicylate, homosalate, avobenzone, carotenoids, free radical scavengers, spin traps, amines, retinoids such as retinol and retinyl palmitate, ceramides, polyunsaturated fatty acids, essential fatty acids, enzymes, enzyme inhibitors, minerals, hormones such as estrogen, steroids such as hydrocortisone, 2-dimethylaminoethanol, copper salts such as copper chloride, copper-containing peptides such as Cu:Gly-His-Lys, coenzyme Q10, peptides, amino acids such as proline, vitamins, lactobionic acid, acetyl-CoA, niacin, riboflavin, thiamine, ribose, such as NADH and FADH 2 Electron transfer substances such as and other plant extracts such as aloe, feverfew, oatmeal, and their derivatives and mixtures. The cosmetic active agent is generally present in an amount of about 0.001% to about 20%, such as about 0.005% to about 10%, such as about 0.01% to about 5%, based on the weight of the skin external preparation of the present invention.

[0061] Examples of vitamins include, but are not limited to, vitamin A, vitamin B (e.g., vitamin B3, vitamin B5, and vitamin B12), vitamin C, vitamin K, and different forms of vitamin E (e.g., α, β, γ, or Δ tocopherol) or mixtures thereof and derivatives thereof.

[0062] Examples of hydroxy acids include, but are not limited to, glycolic acid, lactic acid, malic acid, salicylic acid, citric acid, and tartaric acid.

[0063] Examples of antioxidants include, but are not limited to, water-soluble antioxidants such as sulfhydryl compounds and their derivatives (e.g., sodium metabisulfite and N-acetyl-cysteine), lipoic acid and dihydrolipoic acid, resveratrol, lactoferrin and ascorbic acid and ascorbic acid derivatives (e.g., ascorbyl palmitate and ascorbic acid polypeptide). Oil-soluble antioxidants suitable for use in the skin topical preparations of the present invention include, but are not limited to, butylated hydroxytoluene, retinoids (e.g., retinol and retinyl palmitate), tocopherols (e.g., tocopherol ethyl ester), tocotrienols and ubiquinone. Natural extracts containing antioxidants suitable for use in the skin topical preparations of the present invention include, but are not limited to, extracts containing flavonoids and isoflavones and their derivatives (e.g., genistein and di-zein), extracts containing resveratrol, and the like. Examples of such natural extracts include grape seeds, green tea, pine bark, and propolis.

[0064] How to use

[0065] The skin topical preparation of the present invention can be topically applied to the skin of a mammal of one or more skins in need of treatment. In one embodiment, the skin topical preparation can be applied to the skin in need of whitening and brightening. The skin topical preparation can be applied to the skin in need of such treatment according to a suitable treatment regimen, such as monthly, weekly, every other day, daily, twice a day, etc.

[0066] In certain embodiments, the skin topical preparations of the present invention can also be used to treat other needs related to the skin. For example, the skin topical preparations of the present invention can be used to treat hyperpigmentation after inflammation, to reduce pore size, to reduce sebum production, and to alleviate scars. In certain other embodiments, the skin topical preparations of the present invention can be applied simultaneously with a mechanical or physical epidermal exfoliation treatment (e.g., microdermabrasion treatment) or within a few hours of the treatment, or simultaneously with a chemical peel or keratolytic agent such as salicylic acid. In certain other embodiments, the skin topical preparations of the present invention can be applied to mucous membranes or other tissues such as vaginal tissue, oral tissue, or eye tissue. In certain other embodiments, the skin topical preparations of the present invention can be applied to mild wounds or postoperative sites to promote healing, to insect bites, to poison ivy skin disorders or similar skin conditions, or generally used to relieve itching.

[0067] The present invention is further described below in conjunction with specific examples. It is necessary to point out that the examples are only used to further illustrate the present invention and cannot be construed as limiting the scope of the present invention. Those skilled in the art can make some non-essential improvements and adjustments based on the content of the present invention described above. The test methods in the following examples that do not specify specific conditions are usually based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, all percentages and parts are by weight.

[0068] The stigmasterane mixture used in the present invention (a mixture of stigmasterane-22-ene-3,6-dione and 5α-stigmasterane-3,6-dione in a ratio of about 1:1) has a purity of more than 90%, is derived from chamomile, and is provided by the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences.

[0069] Example 1: Sample preparation

[0070] Weigh 42.77 mg of the stigmasterane mixture, dissolve it with dimethyl sulfoxide (Sigma, DMSO), add an appropriate amount of DMSO and make up to 100 mL volumetric flask to obtain a 427.7 mg / L stigmasterane mixture solution for use.

[0071] Example 2: Sample preparation

[0072] 7.5 mL of Example 1 was taken with a pipette, and an appropriate amount of phosphate buffer was added to a 10 mL volumetric flask and fixed to volume to obtain a 320.78 mg / L stigmasterane mixture solution for use.

[0073] Example 3: Sample preparation

[0074] 5 mL of Example 1 was taken with a pipette, and an appropriate amount of phosphate buffer was added to a 10 mL volumetric flask and fixed to volume to obtain a 213.85 mg / L stigmasterane mixture solution for use.

[0075] Example 4: Sample preparation

[0076] 2.5 mL of Example 1 was taken with a pipette, and an appropriate amount of phosphate buffer was added to a 10 mL volumetric flask and fixed to volume to obtain a 106.95 mg / L stigmasterane mixture solution for use.

[0077] Example 5: Sample preparation

[0078] In a biosafety cabinet, 25 μL of Example 4 was pipetted with a pipette, and culture medium (M-254 culture medium, Guangzhou Boxi Biotechnology) was added to 10 mL to obtain a 0.2673 mg / L stigmasterane mixture solution for use.

[0079] Example 6: Sample preparation

[0080] In a biosafety cabinet, 50 μL of Example 4 was pipetted with a pipette, and culture medium (M-254 culture medium, Guangzhou Boxi Biotechnology) was added to 10 mL to obtain a 0.5346 mg / L stigmasterane mixture solution for use.

[0081] Test Example 1: Tyrosinase activity assay

[0082] The tyrosinase activity test uses L-dopa as the substrate. The test sets up a sample group (T) and a sample background group (T 0 ), enzyme reaction group (C) and solvent control group (C 0 ), the sample group is the stigmasterane mixture solution of Examples 2, 3, 4, and 5. Use a 96-well plate with 200 μL wells to add liquid according to the table below. Three replicate wells are required for each sample well (T) of each tested concentration, and three replicate wells are also required for the enzyme reaction well (C). After sufficient mixing, place in a 37°C incubator and incubate for 10 minutes. Use a microplate reader to detect the absorbance value of the sample at 492 nm. Calculate the tyrosinase inhibition rate:

[0083]

[0084] Table 1: Sample dosing requirements

[0085]

[0086] Table 2: Inhibition of tyrosinase activity

[0087]

[0088] Note: Due to the influence of the test system, the concentration of the prepared test sample will be further diluted 5 times during the test, so the prepared concentration is 5 times the final test concentration. The concentration involved in the test result explanation also refers to the final test concentration.

[0089] As can be seen from Table 2, the tyrosinase inhibition rate of the stigmasterane mixture of Example 1 (427.7 mg / L) is 82.02%, the tyrosinase inhibition rate of the stigmasterane mixture of Example 2 (320.78 mg / L) is 57.02%, the tyrosinase inhibition rate of the stigmasterane mixture of Example 3 (213.85 mg / L) is 32.21%, and the tyrosinase inhibition rate of the stigmasterane mixture of Example 4 (106.95 mg / L) is 21.44%.

[0090] The results showed that in the in vitro tyrosinase activity inhibition experiment, 106.95-427.7 mg / L of stigmasterane mixtures could effectively inhibit tyrosinase activity in a concentration-dependent manner.

[0091] Test Example 2: Determination of Melanin Content

[0092] 1. Test principle: The production of melanin by melanocytes in the skin is the main cause of skin darkening and the formation of spots. Therefore, melanocytes (primary melanocytes, Guangdong Boxi Biology) are used as test tools to evaluate the whitening effect of the sample to be tested by detecting the changes in melanin content.

[0093] 2. Test method:

[0094] 1) Inoculation: 3×10 5 Melanocytes were seeded into 6-well plates at a seeding density of 100 cells / well and incubated in an incubator (37°C, 5% CO 2 ) and incubate overnight.

[0095] 2) Solution preparation: Prepare the working solution of the test substance according to the specific test group (Table 3).

[0096] Table 3: Test groups

[0097]

[0098] 3) Drug administration: According to the test grouping in Table 3, when the cell plating rate in the 6-well plate reaches 40% to 60%, group drug administration is carried out, and the dosage per well is 2 mL. Each group has 3 replicate wells and the cells are incubated in an incubator (37°C, 5% CO 2 ) for 72 h, discard the culture medium (M-254 culture medium, Guangzhou Boxi Biotechnology) after 72 h, and wash once with phosphate buffered saline (PBS).

[0099] 4) Cell digestion: melanocytes were digested with 0.25% trypsin (700 μL / well) at 37° C. for 1-2 minutes, and the reaction was terminated by adding stop solution. After pipetting and mixing, the cells were collected into a 1.5 mL EP tube, centrifuged at 10,000 r / min for 10 minutes, and the supernatant was discarded.

[0100] 5) Add 200 μL of distilled water, 500 μL of anhydrous ethanol and 500 μL of ether to the EP tube in sequence, mix thoroughly, let stand at room temperature for 20 minutes, centrifuge at 3000 r / min for 5 minutes, and discard the supernatant.

[0101] 6) Add 1 mL of 1 mol / L NaOH aqueous solution containing 10% DMSO and heat in a water bath at 80°C for 40 minutes.

[0102] 7) After the heat incubation, pipette 200 μL of supernatant into the corresponding wells of a clearly labeled 96-well plate, read the OD value at 405 nm, and test three replicates for each model on a 96-well plate.

[0103] 3. Experimental results:

[0104] Table 4: Melanin content determination

[0105]

[0106] Note: Inhibition rate (%) = (melanin content of control group - melanin content of sample) / melanin content of control group.

[0107] It can be seen from Table 4 that the melanin content of the stigmasterane mixture of Example 5 (0.2673 mg / L) is 22.64 mg / L, and the corresponding melanin production inhibition rate is 17.29%. The melanin content of the stigmasterane mixture of Example 6 (0.5346 mg / L) is 21.61 mg / L, and the corresponding melanin production inhibition rate is 21.04%.

[0108] The above experimental results can confirm that the stigmasterane mixture can significantly inhibit the production of melanin and has a good whitening effect.

[0109] The stigmasterane mixture of the present invention can be used as an intermediate raw material or an effective additive for the preparation of skin external preparations, medicines and health foods. The skin external preparation is preferably a cosmetic composition, including but not limited to the preparation of products in the form of creams, emulsions, gels, lotions, essences, facial masks, eye creams, aerosols (cleansing bubbles), sprays, shower gels and facial cleansers. The weight percentage of the stigmasterane mixture solutions of Examples 1-7 in the skin external preparation is 0.00002%-20% (w / w). The preferred weight percentage is 0.0001%-10% (w / w). The more preferred weight percentage is 0.001%-5% (w / w). The most preferred weight percentage is 0.01%-5% (w / w).

[0110] The following are specific application examples of the stigmasterane mixture in skin external preparations, medicines and health foods, as well as the formulations and preparation methods of these dosage forms. In the following tables, "-" means no addition.

[0111] Application Example 1: Preparation of facial cream

[0112]

[0113]

[0114] Application Example 2: Preparation of Emulsion

[0115]

[0116]

[0117] Application Example 3: Preparation of Gel

[0118]

[0119] Application Example 4: Preparation of lotion

[0120]

[0121]

[0122] Application Example 5: Preparation of Essence

[0123]

[0124]

[0125] Application Example 6: Preparation of facial mask

[0126]

[0127] Application Example 7: Preparation of Eye Cream

[0128]

[0129]

[0130] Application Example 8: Preparation of Aerosol (Cleaning Bubble)

[0131]

[0132] Application Example 9: Preparation of Spray

[0133]

[0134] Application Example 10: Preparation of Shower Gel

[0135]

[0136] Application Example 11: Preparation of facial cleanser

[0137]

Claims

1. Whitening application of stigmasterane mixture.

2. The use according to claim 1, characterized in that The stigmasterane mixture is used at a concentration of at least 0.2 mg / L.

3. The use according to claim 2, characterized in that The stigmasterane mixture is used at a concentration of at least 0.5 mg / L.

4. The use according to claim 2, characterized in that The stigmasterane mixture is used at a concentration of 0.2 mg / L to 50000 mg / L.

5. The use according to any one of claims 1 to 4, characterized in that: The whitening is to inhibit the activity of tyrosinase.

6. The use according to any one of claims 1 to 4, characterized in that: The whitening is to inhibit the production of melanin.

7. The use according to any one of claims 1 to 4, characterized in that The whitening is to inhibit the generation of spots.

8. Application of stigmasterane mixture in the preparation of skin external preparations, medicines and health foods with whitening effects.

9. The use according to claim 8, characterized in that The content of the stigmasterane mixture in external skin preparations, medicines and health foods is 0.00002-10% by weight.

10. The use according to claim 9, characterized in that The content of the stigmasterane mixture in external skin preparations, medicines and health foods is 0.0001-5% by weight.

11. The use according to claim 8, characterized in that The skin external preparation is selected from: facial cream, lotion, gel, toner, essence, facial mask, eye cream, aerosol cleansing foam, spray, shower gel, or facial cleanser.

12. The use according to any one of claims 8 to 11, characterized in that: The whitening is to inhibit the activity of tyrosinase.

13. The use according to any one of claims 8 to 11, characterized in that: The whitening is to inhibit the production of melanin.

14. The use according to any one of claims 8 to 11, characterized in that: The whitening is to inhibit the generation of spots.